Literature DB >> 19423729

IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Ping Shi1, Raymond Lai, Quan Lin, Abid S Iqbal, Leah C Young, Larry W Kwak, Richard J Ford, Hesham M Amin.   

Abstract

Type I insulin-like growth factor receptor (IGF-IR) tyrosine kinase plays important roles in the pathogenesis of several malignancies. Although it promotes the growth of stimulated hematopoietic cells, a direct role of IGF-IR in malignant lymphoma has not been identified. Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique type of T-cell lymphoma. Approximately 85% of ALK(+) ALCL cases harbor the translocation t(2;5)(p23;q35), which generates the chimeric oncogene NPM-ALK. In the present study, we explored a possible role of IGF-IR in ALK(+) ALCL. Our results demonstrate that IGF-IR and IGF-I are widely expressed in ALK(+) ALCL cell lines and primary tumors. Importantly, we identified novel reciprocal functional interactions between IGF-IR and NPM-ALK. Antagonism of IGF-IR decreased the viability, induced apoptosis and cell-cycle arrest, and decreased proliferation and colony formation of ALK(+) ALCL cell lines. These effects could be explained by alterations of cell survival regulatory proteins downstream of IGF-IR signaling. Our findings improve current understanding of the biology of IGF-IR and NPM-ALK and have significant therapeutic implications as they identify IGF-IR signaling as a potential therapeutic target in ALK(+) ALCL and possibly other types of malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423729      PMCID: PMC2714211          DOI: 10.1182/blood-2007-11-125658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

1.  Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR.

Authors:  J Nakae; V Barr; D Accili
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.

Authors:  Malcolm A Meyn; Matthew B Wilson; Fadi A Abdi; Nathalie Fahey; Anthony P Schiavone; Jiong Wu; James M Hochrein; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

4.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

Authors:  Lin Qiu; Raymond Lai; Quan Lin; Esther Lau; David M Thomazy; Daniel Calame; Richard J Ford; Larry W Kwak; Robert A Kirken; Hesham M Amin
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

5.  Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.

Authors:  L Brugières; P Quartier; M C Le Deley; H Pacquement; Y Perel; C Bergeron; C Schmitt; J Landmann; C Patte; M J Terrier-Lacombe; G Delsol; O Hartmann
Journal:  Ann Oncol       Date:  2000-01       Impact factor: 32.976

6.  Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.

Authors:  M Chikamori; J Fujimoto; N Tokai-Nishizumi; T Yamamoto
Journal:  Oncogene       Date:  2006-11-06       Impact factor: 9.867

7.  Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

Authors:  Carmen J Tartari; Rosalind H Gunby; Addolorata M L Coluccia; Roberta Sottocornola; Barbara Cimbro; Leonardo Scapozza; Arianna Donella-Deana; Lorenzo A Pinna; Carlo Gambacorti-Passerini
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

8.  Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Authors:  Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

9.  Bcr-Abl induces autocrine IGF-1 signaling.

Authors:  A Lakshmikuttyamma; E Pastural; N Takahashi; K Sawada; D P Sheridan; J F DeCoteau; C R Geyer
Journal:  Oncogene       Date:  2008-02-04       Impact factor: 9.867

10.  Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.

Authors:  Ping Shi; Joya Chandra; Xiaoping Sun; Mate Gergely; Jorge E Cortes; Guillermo Garcia-Manero; Ralph B Arlinghaus; Raymond Lai; Hesham M Amin
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

View more
  29 in total

1.  Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.

Authors:  Todd A Triplett; Kim T Cardenas; Jessica N Lancaster; Zicheng Hu; Hilary J Selden; Guadalupe J Jasso; Sadhana Balasubramanyam; Kathy Chan; LiQi Li; Xi Chen; Andrea N Marcogliese; Utpal P Davé; Paul E Love; Lauren I R Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

2.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

3.  Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.

Authors:  Zhiwei Huang; Zhijia Fang; Hong Zhen; Li Zhou; Hesham M Amin; Ping Shi
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 4.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

5.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

Review 6.  Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

Authors:  J de Castro-Carpeño; R Perona; C Belda-Iniesta
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

7.  Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.

Authors:  Thomas Strömberg; Xiaoying Feng; Maryam Delforoush; Mattias Berglund; Yingbo Lin; Magnus Axelson; Olle Larsson; Patrik Georgii-Hemming; Johan Lennartsson; Gunilla Enblad
Journal:  Med Oncol       Date:  2015-05-29       Impact factor: 3.064

8.  MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.

Authors:  Deeksha Vishwamitra; Yong Li; Desiree Wilson; Roxsan Manshouri; Choladda V Curry; Bin Shi; Xi Ming Tang; Andrea M Sheehan; Ignacio I Wistuba; Ping Shi; Hesham M Amin
Journal:  Am J Pathol       Date:  2012-03-10       Impact factor: 4.307

9.  Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.

Authors:  Deeksha Vishwamitra; Ping Shi; Desiree Wilson; Roxsan Manshouri; Francisco Vega; Ellen J Schlette; Hesham M Amin
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

10.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.